Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2019
Reporting Period: Quarter and year ended December 31, 2018
Context: The filing announces the issuance of a press release containing financial results for the period ended December 31, 2018, and details regarding a conference call to discuss these results and business updates.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) and a presentation (Exhibit 99.2) where the actual figures are located. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not describe specific material changes versus the prior comparable period. It serves only to notify investors that results for the quarter and year ended December 31, 2018, have been released via a separate press release.
Guidance, Outlook, and Risks
Management Commentary: The company scheduled a conference call to discuss financial results and business updates. A presentation accompanying this call is included as Exhibit 99.2.
Legal Status: The information in Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure), including the press release and presentation, is furnished and not deemed "filed" under the Securities Exchange Act of 1934. It is not subject to Section 18 liability nor incorporated by reference into other filings unless expressly stated.
Emerging Growth Company: The registrant is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2018.
- Review Exhibit 99.2 (Company Presentation) for management's outlook, pipeline updates, and guidance.
- Verify the company's status as an emerging growth company and its election regarding accounting standard transition periods.
- Confirm that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in this 8-K.